Some remaining challenges regarding multiple endpoints in clinical trials-Reference-Cited by-同舟云学术

Some remaining challenges regarding multiple endpoints in clinical trials

Published:2017-06-30 Issue:28 Volume:36 Page:4441-4445
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Snapinn Steven¹^ORCID

Affiliation:

1. Amgen Inc.; One Amgen Center Drive, 24-2-C Thousand Oaks CA 91320 U.S.A.

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Reference16 articles.

1. Key multiplicity issues in clinical drug development;Dmitrienko;Statistics in Medicine,2013

2. FDA Draft Guidance for Industry Multiplicity Endpoints in Clinical Trials, January 2017 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM536750.pdf

3. Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go;Snapinn;Pharmaceutical Statistics,2011

4. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study;Meltzer;American Journal of Psychiatry,2011

5. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;New England Journal of Medicine,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When should factorial designs be used for late-phase randomised controlled trials?;Clinical Trials;2023-10-31

2. Variation in Endpoints in FDA Medication Approvals;Neurology;2023-09-05

3. Evaluating Treatment Efficacy by Combining Multiple Measures in Clinical Trial Applications;Pharmaceutical Medicine;2022-12-02

4. Day versus night in the catheterization laboratory: all the same;Polish Archives of Internal Medicine;2020-08-27

5. Measuring outcomes in self-harm trials: what is important and what is achievable?;BJPsych Open;2020-02-12